Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
New England Journal of Medicine · 23.11.2023 · 389 (21) · 1935-1948
DOI: 10.1056/nejmoa2306434 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.11.2023. Verfasst von David Planchard und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, and the Fa…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 782-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AstraZeneca.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Medical Oncology, Institut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, and the Faculty of Medicine, Paris-Saclay University, Paris - both in France (D.…
ORCID-Profile: Jonathan Goldman
Förderung
- AstraZeneca
Zitieren
APA
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C., Yanagitani, N., Kim, S. W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., Laktionov, K., Lee, C. K., Valdiviezo, N., Ahmed, S., Maurel, J. M., Andrasina, I., Goldman, J., Ghiorghiu, D., Rukazenkov, Y., …, & FLAURA2 Investigators (2023). Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 389(21), 1935-1948. https://doi.org/10.1056/nejmoa2306434
Vancouver
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2023;389(21):1935-1948. doi:10.1056/nejmoa2306434
BibTeX
@article{Planchard2023,
author = {Planchard, David and Jänne, Pasi A and Cheng, Ying and Yang, James C-H and Yanagitani, Noriko and Kim, Sang-We and Sugawara, Shunichi and Yu, Yan and Fan, Yun and Geater, Sarayut L and Laktionov, Konstantin and Lee, Chee K and Valdiviezo, Natalia and Ahmed, Samreen and Maurel, Jean-Marc and Andrasina, Igor and Goldman, Jonathan and Ghiorghiu, Dana and Rukazenkov, Yuri and Todd, Alex and Kobayashi, Kunihiko and FLAURA2 Investigators, FLAURA2 Investigators},
title = {Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {21},
pages = {1935--1948},
doi = {10.1056/nejmoa2306434}
}
EUVIMED